Recap - What a week. The iShares NASDAQ Biotechnology (IBB) made new all-time highs and is drastically outpacing the S&P 500, as well as the NASDAQ composite, for the … Continue Reading
Read nowInsights - In last week’s biotech recap, and again at PropThink.com this week, we outlined some key support levels for the S&P 500 (SPX or SPY), explaining … Continue Reading
Read nowInsights - At a medical meeting this week Alnylam Pharmaceuticals (ALNY) reported six-month data from an ongoing study of patisiran (ALN-TTR02) in the rare disorder TTR-mediated amyloidosis (ATTR) in patients with … Continue Reading
Read nowResearch - Late-breaking abstracts from AASLD’s upcoming The Liver Meeting were published on Tuesday morning at 10:00 AM, and a number of companies with development-stage therapeutics in the space felt the impact. … Continue Reading
Read nowRecap - Johnson & Johnson (JNJ) is shelling out $1.75 billion to acquire Alios Biopharma, a private developer of therapeutics for viral diseases. Alios’ lead drug asset … Continue Reading
Read nowInsights - Just after the close on Tuesday the United States’ Centers for Disease Control and Prevention (CDC) confirmed the first infection of Ebola Zaire in a … Continue Reading
Read nowRecap - Six weeks after Federal Reserve Chairwoman Janet Yellen called biotechnology valuations “substantially stretched” the NASDAQ Biotechnology Index (IBB) is setting new records right alongside the S&P 500. It’s … Continue Reading
Read now
